Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healthcare Conference
November 24 2020 - 8:00AM
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the
“company”), a technology company providing comprehensive testing
solutions through its scalable technology platform, today announced
that its Chairman and Chief Executive Officer Ming Hsieh, Chief
Financial Officer Paul Kim, and Chief Commercial Officer Brandon
Perthuis virtually participated in a pre-recorded fireside chat
that will be published as part of the Piper Sandler 32nd Annual
Healthcare Conference taking place December 1 to 3, 2020.
Management will also be conducting virtual one-on-one investor
meetings during the conference.
A webcast of the fireside chat will be available on the Investor
Relations section of the Fulgent Genetics website at
ir.fulgentgenetics.com, and will be available for 90 days following
the conference.
About Fulgent
Genetics
Fulgent Genetics’ proprietary technology platform has created a
broad, flexible test menu and the ability to continually expand and
improve its proprietary genetic reference library while maintaining
accessible pricing, high accuracy and competitive turnaround times.
Combining next generation sequencing (“NGS”) with its technology
platform, the company performs full-gene sequencing with
deletion/duplication analysis in an array of panels that can be
tailored to meet specific customer needs. In 2019, the company
launched its first patient-initiated product, Picture Genetics, a
new line of at-home screening tests that combines the company’s
advanced NGS solutions with actionable results and genetic
counseling options for individuals. Since March 2020, the company
has commercially launched several tests for the detection of
SARS-CoV-2, the virus that causes the novel coronavirus
(“COVID-19”), including NGS and reverse transcription polymerase
chain reaction (“RT-PCR”) - based tests. The company has received
Emergency Use Authorization (“EUA”) from the U.S. Food and Drug
Administration (“FDA”) for the RT-PCR-based tests for the detection
of SARS-CoV-2 using upper respiratory specimens (nasal,
nasopharyngeal, and oropharyngeal swabs) and for the at-home
testing service through Picture Genetics. A cornerstone of the
company’s business is its ability to provide expansive options and
flexibility for all clients’ unique testing needs through a
comprehensive technology offering including cloud computing,
pipeline services, record management, web portal services, clinical
workflow, sequencing as a service and automated laboratory
services.
Investor Relations
Contacts:The Blueshirt
GroupNicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Apr 2023 to Apr 2024